Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases

Abstract

The invention relates to pharmacology and medicine, in particular to a class of mitochondrially-addressed compounds which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases and diseases and pathological conditions caused by disturbed blood circulation or oxygen supply to tissues and organs.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . A pharmaceutical antioxidant formulation comprising about 740 ng/g to about 9.3 mg/g SkQ1 having the structure: 
       
         
           
           
               
               
           
         
         and its reduced form SkQ1H2: 
       
       
         
           
           
               
               
           
         
         wherein Z −  is a pharmacologically acceptable anion. 
       
     
     
         4 . (canceled) 
     
     
         5 . A pharmaceutical antioxidant formulation comprising about 6.0 μg/g to about 7.5 mg/g SkQ3 having the structure: 
       
         
           
           
               
               
           
         
         and its reduced form SkQ3H2: 
       
       
         
           
           
               
               
           
         
         
           wherein Z −  is a pharmacologically acceptable anion. 
         
       
     
     
         6 .- 36 . (canceled) 
     
     
         37 . A pharmaceutical antioxidant formulation comprising about 740 ng/g to 9.3 mg/g SkQ1 in pill, capsule, or suppository form, or about 740 ng/ml to 9.3 mg/ml SkQ1 in liquid intravenous or oral form, having the structure: 
       
         
           
           
               
               
           
         
         and its reduced form SkQ1H2: 
       
       
         
           
           
               
               
           
         
         wherein Z −  is a pharmacologically acceptable anion. 
       
     
     
         38 . A pharmaceutical antioxidant formulation for oral administration, comprising about 1.5 μg/g to about 3 mg/g SkQ having the structure: 
       
         
           
           
               
               
           
         
       
       wherein:
 A is the effector/antioxidant moiety: 
 
       
         
           
           
               
               
           
         
         
           and/or reduced form thereof, wherein:
 m is an integer from 1 to 3; and 
 each Y is methyl; 
 
           L is a linker group, comprising:
 a) a straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds; or 
 b) a natural isoprene chain; 
 
           n is an integer from 1 to 20; and 
           B is a targeting group comprising Sk + Z − , wherein:
 Sk +  is a lipophilic cation; and 
 Z −  is a pharmacologically acceptable anion; and 
 
           a pharmaceutically acceptable carrier thereof. 
         
       
     
     
         39 . A pharmaceutical antioxidant formulation for intravenous administration, comprising about 6.0 μg/ml to about 7.5 mg/ml SkQ having the structure: 
       
         
           
           
               
               
           
         
       
       wherein:
 A is the effector/antioxidant moiety: 
 
       
         
           
           
               
               
           
         
         
           and/or reduced form thereof, wherein:
 m is an integer from 1 to 3; and 
 each Y is methyl; 
 
         
         L is a linker group, comprising:
 a) a straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds; or 
 b) a natural isoprene chain; 
 
         n is an integer from 1 to 20; and 
         B is a targeting group comprising Sk + Z − , wherein:
 Sk +  is a lipophilic cation; and 
 Z −  is a pharmacologically acceptable anion; and 
 
         a pharmaceutically acceptable carrier thereof.